China’s New Stem Cell Guidelines To Shake Up Industry?
This article was originally published in PharmAsia News
China is releasing additional regulations governing clinical trials with stem cell therapies following its first new administrative measures this year, in order to better regulate the market. The changes are expected to result in a reshuffle of the industry and the flushing out of up to 80% of companies currently involved in the field, with the focus of the supply chain set to shift to the middle ground.
You may also be interested in...
Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.
Strongbridge obtains rights from AEterna Zentaris to first drug approved for adult growth hormone deficiency. While the J.P. Morgan Healthcare Conference didn't have many major deal announcements, there was a flurry of announcements around discovery and development capabilities.